Patents by Inventor Roger Strair

Roger Strair has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treatment for acute myelogenous leukemia
    Patent number: 8575216
    Abstract: This invention relates to a method of treating acute myelogenous leukemia with TPA along with Dexamethasone and choline magnesium trisalicylate.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: November 5, 2013
    Assignee: Rutgers, The State University of New Jersey
    Inventor: Roger Strair
  • Method of Treatment for Acute Myelogenous Leukemia
    Publication number: 20110034425
    Abstract: This invention relates to a method of treating acute myelogenous leukemia with TPA along with Dexamethasone and choline magnesium trisalicylate.
    Type: Application
    Filed: August 4, 2010
    Publication date: February 10, 2011
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventor: Roger Strair
  • Drug combination for the treatment of viral diseases
    Patent number: 6576622
    Abstract: This invention pertains to a method for treating a human with human immunodeficiency virus infection which comprises administering to the human a therapeutically effective amount of a thymidine analog, which analog acts as an inhibitor of viral reverse transcriptase necessary for viral replication of human immunodeficiency virus, and a thymidylate synthase inhibitor, or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 10, 1997
    Date of Patent: June 10, 2003
    Assignee: University of Medicine & Dentistry of New Jersey
    Inventors: Roger Strair, Daniel Medina, Peter Tung
  • Drug combination for the treatment of viral diseases
    Publication number: 20030100533
    Abstract: This invention pertains to a method for treating a human with human immunodeficiency virus infection which comprises administering to the human a therapeutically effective amount of a thymidine analog, which analog acts as an inhibitor of viral reverse transcriptase necessary for viral replication of human immunodeficiency virus, and a thymidylate synthase inhibitor, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: May 17, 2002
    Publication date: May 29, 2003
    Applicant: UNIVERSITY OF MEDICINE & DENTISTRY OF NEW JERSEY
    Inventors: Roger Strair, Daniel Medina, Peter Tung
  • HIV-1 vectors
    Patent number: 5837512
    Abstract: The present invention pertains to a genetically altered human immunodeficiency virus type 1 (HIV-1) which replicates only in human CD4+ cells that express the Tax protein of Human T-cell Lymphotropic Virus Type I (HTLV-I), wherein the HIV long terminal repeat (LTR) promoter and enhancer sequences (NF-kappa-B and Sp1 binding sites) of the genetically altered human immunodeficiency virus type 1 have been replaced by two copies of the HTLV-I LTR 21 base pair repeat Tax-responsive element (TRE). The present invention also pertains to methods for killing HTLV-1 infected cells in humans with HTLV-1 disease (HTLV-1 tumors and HAM/TSP) with the novel genetically altered human immunodeficiency virus type 1 (HIV-1).
    Type: Grant
    Filed: December 14, 1995
    Date of Patent: November 17, 1998
    Assignee: University of Medicine & Dentistry of NJ
    Inventors: Arnold B. Rabson, Hsin-Ching Lin, Marion Bodkin, Roger Strair